risks of glp 1 agonists Do The Benefits GLP-1 Drugs OutWeigh the Negatives? The promise and peril of

However, regulatory eligibility differs from clinical suitability

The first GLP-1 injectable receptor agonist exenatide was approved by the U.S

However, because of their lesser magnitude of glucose lowering, they are prescribed more commonly as an addition to another type of medicine rather than as monotherapy: Metformin: First-line therapy that decreases hepatic glucose output

Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial

Tran Marie, T.D

However, if you experience severe abdominal pain that doesnt go away, contact your healthcare provider immediately